Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin
References
- World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; 2016.
http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf [Accessed 8 February 2020]. - World Health Organization. Regional action plan for viral hepatitis in the Western Pacific 2016–2020. Manila: World Health Organization regional office for the Western Pacific; 2016.
https://iris.wpro.who.int/bitstream/handle/10665.1/13141/97892906177617_eng.pdf [Accessed 8 February 2020]. - World Health Organization. Hepatitis data and statistics in the Western Pacific. Epidemiological estimates for viral hepatitis in the Western Pacific.
https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data [Accessed 8 February 2020]. - World Health Organization. Work conducted by the London School of Hygiene & Tropical Medicine. 2 December 2016.
http://whohbsagdashboard.com/#global-strategies [Accessed 8 February 2020]. - Chinese Society of Liver Diseases and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C: A 2015 update. Chinese Journal of Hepatology. 2015; 23: 906–923 (in Chinese). DOI: 10.3760/cma.j.issn.1007-3418.2015.12.003
- National Health Commission. Bureau of Disease Control. Prevention and control of communicable diseases.
http://www.nhc.gov.cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c.shtml [Accessed 8 February 2020] (in Chinese). - Moon S, Erickson E. Universal medicine access through lump-sum remuneration — Australia’s approach to hepatitis C. N Engl J Med. 2019; 380: 607–610. DOI: 10.1056/NEJMp1813728
- Fonseca EM, Shadlen K, Bastos F. Brazil’s fight against hepatitis C — Universalism, local production, and patents. N Engl J Med. 2019; 380: 605–607. DOI: 10.1056/NEJMp1812959
- National Health Commission. National viral hepatitis prevention and control (2017–2020).
http://www.nhc.gov.cn/ewebeditor/uploadfile/2017/11/20171113134002475.pdf [Accessed 8 February 2020] (in Chinese). - National Health Commission. National diagnosis standard for hepatitis C.
http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/03/20180330092842208.pdf [accessed 8 February 2020] (in Chinese). - National Medical Products Administration. Database search.
http://app1.sfda.gov.cn/datasearchcnda/face3/dir.html?type=yp [Accessed 8 February 2020] (in Chinese). - Zhuang H, Wei L, Yang X. Current situation of hepatitis C and prevention & treatment strategies in China. Beijing: People’s Health Publishing House; 2017 (in Chinese).
- National Health Commission. The announcement of issuing the 2018 National Essential Medicines. Document No. 31 of 2018.
http://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a3940d08d996b588d941631.shtml [Accessed 8 February 2020] (in Chinese). - Zhejiang Province Human Resource and Social Security Department. The announcement of including 28 medicines into the health insurance reimbursement list. (ZJSP13-2018-0001)
http://www.zjhrss.gov.cn/art/2018/1/16/art_1443137_9238.html [Accessed 8 February 2020] (in Chinses). - Tianjin Statistics Bureau. Population.
http://stats.tj.gov.cn/Category_1/Index.aspx [Accessed 8 February 2020] (in Chinese). - Chen J, et al. Investigation on hepatitis C virus infection and hepatitis C virus infection in Tianjin residents. Shandong Medicine. 2015; 22: 86–87 (in Chinese). DOI: 10.3969/j.issn.1002-266X.2015.22.035
- Wu W, et al. Mortality and epidemiological characteristics of hepatocellular carcinoma associated with hepatitis B and C virus in Tianjin. Journal of Preventive Medicine Information. 2016; 32(9): 941–944 (in Chinese).
- He H, et al. Prevalence of hepatitis C in Tianjin, China and related risk factors. Chinese Journal of Hepatology. 2016; 4: 647–651. (in Chinese).
- Tianjin Center for Disease Prevention and Control. Reporting system of notifiable communicable diseases.
http://www.cdctj.com.cn/system/2016/02/18/013082454.shtml [Accessed 8 February 2020] (in Chinese). - The Data Center of China Public Health Science. Communicable diseases. Hepatitis.
http://www.phsciencedata.cn/Share/ky_sjml.jsp?id=8defcfc2-b9a4-4225-b92c-ebb002321cea [Accessed 8 February 2020] (in Chinese). - Tianjin Municipal Human Resources and Social Security Bureau. The announcement of implementing a capitated provider payment pilot for outpatient care of hepatitis C of Tianjin basic health insurance. Document No.74 of 2018.
http://hrss.tj.gov.cn/ecdomain/framework/tj/gnnknhmjegifbbodkjajlpafcampibii/innplgdkegifbbodkjajlpafcampibii.do?isfloat=1&fileid=20180328130120135&moduleIDPage=innplgdkegifbbodkjajlpafcampibii&siteIDPage=tj&pageID=gnnknhmjegifbbodkjajlpafcampibii [Accessed 8 February 2020] (in Chinese). - Tianjin Municipal Human Resources and Social Security Bureau. Premium and benefit package of rural residents. Document No 41 of 2013.
http://hrss.tj.gov.cn/ecdomain/framework/tj/ckoocoapccolbbogkjpnifpkdgnfeahc/clbhpndaccolbbogkjpnifpkdgnfeahc.do?isfloat=1&fileid=20130428083007295&moduleIDPage=clbhpndaccolbbogkjpnifpkdgnfeahc&siteIDPage=tj&pageID=ckoocoapccolbbogkjpnifpkdgnfeahc [Accessed 8 February 2020] (in Chinese). - Tianjin Municipal Human Resources and Social Security Bureau. Subsidy to catastrophic medical expenses. Document No 321 of 2001.
http://hrss.tj.gov.cn/ecdomain/framework/tj/ckoocoapccolbbogkjpnifpkdgnfeahc/clbhpndaccolbbogkjpnifpkdgnfeahc.do?isfloat=1&fileid=20081114155807953&moduleIDPage=clbhpndaccolbbogkjpnifpkdgnfeahc&siteIDPage=tj&pageID=ckoocoapccolbbogkjpnifpkdgnfeahc [Accessed 8 February 2020] (in Chinese). - Ni S, Wang L. Chronic hepatitis C treatment cost is reduced in Tianjin. Tianjin Social Insurance. 2014; 9(03): 30–31 (in Chinese).
- Fu W, et al. Comparison of capitated and fee-for-service payment methods for chronic hepatitis C. Tianjin Social Insurance. 2017; 12: 48–49 (in Chinese).
- Wan B, Ding H, Zhan Y. Expenditure and payment method study of hepatitis C treatment. China Health Insurance. 2017; 10: 59–61. DOI: 10.19546/j.issn.1674-3830.2017.10.013 (in Chinese).
- Chinese Society of Liver Diseases, Chinese Medical Association. Hepatitis C treatment guideline. Chinese Journal of Internal Medicine. 2004; 43: 551–555 (in Chinese).
- Finalizada a compra de los medicamentos para hepatitis C en Brasil. 17 de enero de 2019.
http://www.hepato.com/es/2019/01/finalizada-compra-dos-medicamentos-para-hepatite-c/ [Accessed 8 February 2020] (in Portuguese). China National Health and Development and Research Center of the National Health and Family Planning Commission of P.R. China . China health account report. Beijing: CNHDRC; 2017 (in Chinese).- Chen J. Study on the epidemic analysis and report quality of hepatitis C in Tianjin. Tianjin Medical University. Master Dissertation 2016 (in Chinese).
- World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries (WHO/CDS/HIV/18.4). License: CC BY-NC-SA 3.0 IGO., March 2018. Geneva: WHO.
- China Daily USA. China Society. Cancer patients look to India for lifesaving drugs. (2015-01-28).
http://usa.chinadaily.com.cn/china/2015-01/28/content_19426279.htm [Accessed 8 February 2020] (in Chinese). - Lucas C. Dying to survive and cancer care in China. Available online 3 January 2019. The Lancet Oncology. 2019; 20: 30. DOI: 10.1016/S1470-2045(18)30921-5
DOI: https://doi.org/10.5334/aogh.2763 | Journal eISSN: 2214-9996
Language: English
Published on: Apr 6, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2020 Peiwen Zhang, Ran Guo, Jun Lian, Mengjia Zhi, Chengzhen Lu, Weishen Wu, Lihong Wang, Polin Chan, Zhongdan Chen, Jing Sun, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.